Vici Health Sciences Applies to Import Controlled Substances
Estimated reading time: 3 minutes
On August 21, 2025, the United States Department of Justice released a notice about a new application from Vici Health Sciences, LLC. The notice was published in the Federal Register, Volume 90, Number 160.
Vici Health Sciences, LLC has asked to become an importer of certain controlled substances. The company is located at 6655 Amberton Drive, Suite O, Elkridge, Maryland 21075-6202.
The requested substance is fentanyl-related compounds. This drug is listed under code 9850 and is a Schedule I controlled substance, as defined in 21 CFR 1308.11(h).
The company plans to import this substance as part of a manufacturing process. The purpose is to support research and clinical trial efforts. No other uses of this drug are allowed under this registration.
The Drug Enforcement Administration (DEA) has stated that only certain business activities are allowed. These must match the rules in 21 U.S.C. 952(a)(2). The permit does not allow the import of finished drug products for sale, whether approved or not approved by the Food and Drug Administration.
Registered bulk manufacturers and other applicants of the listed class can send electronic comments or objections about this application. The deadline for comments or to request a hearing is September 22, 2025. Comments must be submitted through the Federal eRulemaking Portal at https://www.regulations.gov.
Requests for a hearing must be sent to the Drug Enforcement Administration at 8701 Morrissette Drive, Springfield, VA 22152. Requests should be sent to the Hearing Clerk/OALJ, DEA Federal Register Representative/DPW, and the DEA Administrator at the same address.
The notice was signed by Justin Wood, Acting Deputy Assistant Administrator.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
